Modeling Patient Response to a Therapeutic Diet in Crohn's Disease

Crohn Disease Clinical Trial

— TDI  

Official title:

Can Personalized Diet Therapy Favourably Impact Disease Severity in Patients With Crohn's Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04596566
• Other study ID #: REB19-0402
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 20, 2020
• Est. completion date: June 12, 2023

Study information

• Verified date: October 2020
• Source: University of Calgary
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BACKGROUND: There is an urgent need to understand the role of therapeutic dietary interventions on the treatment of inflammatory bowel disease (IBD). Although nutritional observational studies have examined associations between diet and the development of IBD, the relationship between dietary components and disease relapse is lacking. Despite the lack of a well-defined relationship between dietary determinants and disease relapse, patients with IBD frequently have a strong belief that diet has a key role in controlling the course of their disease, and maybe a trigger of disease relapse. This proposed randomized controlled trial (RCT) explores the efficacy of a Crohn's Disease (CD) Therapeutic Dietary Intervention (TDI) compared to conventional management (CM) to induce steroid-free clinical remission at week 13 in patients with active, mild-to-moderate luminal CD. For asymptomatic patients with active disease, efficacy of the diet will be explored by using fecal calprotectin and sonographic findings Rationale: Our team of investigators recently compared a representative healthy population to patients with CD and identified CD patients have: lower intakes of polyunsaturated and monounsaturated fats and multiple micronutrients (vitamins C, D, thiamine magnesium, phosphorus, zinc, potassium), and; few patients with CD met criteria for an anti-inflammatory dietary pattern. Since the diet is a modifiable potential risk factor for disease recurrence in IBD, there is a strong rationale for the investigation of diet on disease course. Additionally, patients have expressed strong interest in identifying the relationships between diet and disease, therefore assigning priority to this theme is an opportunity to advance patient-oriented care.

Description:

OBJECTIVES: Primary objectives A) Symptomatic patients at the time of recruitment: Harvey Bradshaw Index (HBI) >5 to <16 1. To compare the proportion of patients in each study group at week 13 who are in corticosteroid-free (CF) clinical remission as measured by a Harvey Bradshaw Index (HBI) of <5 (primary endpoint) 2. To compare the proportion of patients in each study group at week 13 who are in biochemical remission as measured by a fecal calprotectin (FCP) of <250ug/g (primary endpoint). B) Asymptomatic patients with active disease at the time of recruitment: Harvey Bradshaw Index (HBI) <5 1. To compare the proportion of patients in each study group at week 13 who are in biochemical remission as measured by a fecal calprotectin (FCP) of <250ug/g (primary endpoint). 2. To compare the proportion of patients in each study group at week 13 who are in clinical remission as measured by sonographic findings of inflammation (Bowel Wall thickening ≤ 3mm). Secondary Hypothesis: The aim of the secondary objectives are to examine whether the dietary intervention has a significant effect on the gut microbiota and SCFAs in patients and whether this is associated with the intervention and disease recurrence at or before 13 weeks. The aim is also to examine whether the intervention has a significant effect on health-related quality of life. - To identify the presence of within and between-group differences in microbial diversity, microbial composition, and abundance of short-chain fatty acids (SCFA) and SCFA-producing bacteria at baseline and 13weeks. - To identify the presence of within and between-group differences in fecal SCFA concentrations at baseline and 13 weeks. To compare the proportion of patients in each study group at week14 that achieve clinical response (decrease in HBI>3points) METHODS: Randomized controlled trial design: This 3-year study, investigator-blinded, RCT (N=102) at the University of Calgary (UoC). Eligible participants will be randomly allocated in a 2:1 ratio to either the intervention group (CD-TDI) or conventional management (CM) alone (i.e., control group) for 13 weeks. Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24 hour food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare. Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 102
• Est. completion date: June 12, 2023
• Est. primary completion date: February 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• (a)=18 years;
• (b)diagnosis of mild-to-moderate luminal ileal, ileo-colonic or colonic CD
• (c) active disease with Harvey Bradshaw Index (HBI) <16 at time of recruitment;
• (d) for active symptomatic patients (HBI > 5 to <16) evidence of endoscopic disease activity within six months of enrolment (presence of ulceration =5mm ) and for active asymptomatic patients (HBI <5) sonographic findings of intestinal inflammation =3mm of bowel wall thickening)
• (e) biomarker evidence of inflammation fecal calprotectin at enrolment (FCP
• 250microg/g).
• (f) < OR = 1 small bowel resection,
• (g) ability to provide informed consent

Exclusion Criteria:

• HBI >16 at time of recruitment;
• (b) fecal calprotectin < 250 microg/mg within 1 month prior to study enrollment;
• (c) patients with upper GI tract CD;
• (d) evidence of perianal or fistulizing disease; (
• e) >1 bowel surgery;
• (f) significant chronic disorders such as cardiac disease, renal failure, active pulmonary disease (these factors may influence dietary intake),
• (g) any psychiatric or neurocognitive comorbidity that would limit ability to follow an CD-TDI
• (h) laxative or antibiotics in the past 3 months and
• (i) presence of ostomy.

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Other:
• Therapeutic diet Intervention
The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1

Locations

Country	Name	City	State
Canada	TRW building, Foothills, University of Calgary	Calgary	Alberta

Sponsors (7)

Lead Sponsor	Collaborator
University of Calgary	Alphabiomics, Crohn's and Colitis Foundation, University of Alberta, University of Birmingham, University of British Columbia, University of Guelph

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fecal calprotectin: Change is being assessed.	<250 ug/mg with at least 100ug/g decline from baseline. FCP is a test used to detect inflammation in the colon and is associated with disease activity and severity.	baseline, 7 and 13 weeks.
Primary	Harvey Bradshaw Index (HBI): Change is being assessed	HBI is a validated, non-invasive measure of disease activity captured through a symptom questionnaire and is a surrogate to endoscopic assessment to determine disease severity. HBI minimum value is "0" and maximum no limit. HBI < 5 is used in this study to indicate clinical remission. HBI> 16 means severe disease activity. Higher scores means worse outcomes. Based on experience with past recruitment for clinical trials, endoscopic assessment is not feasible due to access and patient acceptance.	baseline, 7 and 13 weeks.
Primary	Bowel wall thickness on sonographic findings and Fecal calprotectin: Change is being assessed.	For asymptomatic patients with active disease at the time of recruitment (HBI <5 ) a combined primary endpoint using both FCP <250 ug/mg with at least 100ug/g decline from baseline and ultrasound findings of bowel wall thickening will be used.( = 3mm).	baseline, 7 and 13 weeks for fecal calprotectin and baseline and week 13 for sonographic findings
Secondary	Fecal Microbiota Sequencing: change is being assessed.	Microbiome composition will be measured using shotgun metagenomic sequencing	baseline, 7 and 13 weeks
Secondary	Short chain fatty acids: Change is being assessed	Concentrations of fecal SCFA will be measured according to our previously published protocol. Fecal samples (150 mg) will be added to 1000 µL of 0.005 M aqueous sodium hydroxide containing internal standard (D3 caproic acid), and homogenized for 3 cycles using Fast Prep-24TM homogenizer (MP Biomedicals, Santa Anna, USA). The supernatant will be collected after centrifugation at 14,000 x g for 20 min. The derivatization using propyl chloroformate and analysis of the SCFAs using gas chromatography-mass spectrometry (GC-MS/MS) will be done as previously described	baseline, 7 and 13 weeks
Secondary	Health related quality of life: Change is being assessed.	Health-related quality of life will be measured using the 12-item short form-12. It comprises of two components physical health and mental Health. Scores range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health.	baseline, 7 and 13 weeks
Secondary	Subjective global assessment: Change is being assessed	subjective global assessment is a validated tool to determine malnutrition status in patients with chronic disease. It is scored as A: Well-nourished; B: Mildly/moderately malnourished; C:Severely malnourished. "A" mean normal; "B" means some progressive nutritional loss; "C": means there is evidence of wasting and progressive symptoms	baseline, 7 and 13 weeks
Secondary	Dietary intake: Change is being assessed	Dietary intake and supplement use will be assessed at baseline (week 0),week 7 and week 13 using 2-24 Hour recalls using the multipass method.	baseline, 7 and 13 weeks
Secondary	Sedentary time: Change is being assessed	Sedentary time, will be assessed by the ActivPAL® inclinometer (PALTechnologies, Glasgow). ActivPAL® monitors are the most validated and widely used devices for measuring sitting, standing, and moving/stepping (and transitions in between). Inclinometers are small electronic devices worn discretely on the upper thigh. They measure duration and frequency of time spent sitting, standing and stepping (light ambulation), and number of postural changes. Materials: To capture all activities occurring throughout the day the ActivPAL® (captures lying, sitting, standing, and stepping).	Baseline and week 13
Secondary	CRP: Change is being assessed	C-reactive protein (mg/L)	Baseline and week 13
Secondary	Ferritin: Change is being assessed	Ferritin (Microgram/Litre)	Baseline and week 13
Secondary	Albumin: Change is being assessed	Albumin (g/L)	Baseline and week 13
Secondary	Vitamin D: Change is being assessed	Vitamins D (25OHD3) (nmol/L)	Baseline and week 13
Secondary	Cr: Change is being assessed	Creatinine( µmol/L)	Baseline and week 13
Secondary	Electrolytes: Change is being assessed	Electrolytes: Sodium (Na), potassium (K), chloride (Cl) mmol/L	Baseline and week 13
Secondary	Hb: Change is being assessed	Hemoglobin (Hb) (g/L)	Baseline and week 13
Secondary	Platelet: Change is being assessed	Platelet count (/L)	Baseline and week 13
Secondary	WBC: Change is being assessed	White blood cell count (WBC) (/L)	Baseline and week 13